發表於 美國最新研究顯示，5至11歲兒童接種兩劑輝瑞BioNTech新冠疫苗，預防感染新冠病毒的保護率，會在短時間內急跌至一成二，專家分析認為同疫苗注射劑量有關。輝瑞BioNTech新冠疫苗是美國唯一獲批准可以讓5至11歲兒童接種的新冠疫苗。
紐約州衞生部檢視去年12月13日至今年1月31日、Omicron變種病毒肆虐期間，比較了85.2萬多名12至17歲的少年和36.5萬多名5至11歲的兒童，接種了兩劑輝瑞疫苗後出現重症和住院的情況，發現年紀較大的組別由85%降至73%，年紀較小的組別則由100%跌至48%，但由於兒童留院的數字不多，所以誤差範圍很大。
至於疫苗預防感染新冠病毒的保護率，年紀較大的組別由最初的60%降至51%，年紀較細的組別就由最初的68%，約1個半月後大幅降至只有12%。有免疫學專家相信同疫苗注射劑量有關，因為12歲少年和成年人同樣每劑注射30毫克，但11歲以下的兒童則只注射成年人三分之一的劑量，即是10毫克，疫苗保護率的數據令人失望，但並不意外。
叫班BNT Sales出嚟解釋下好喎！
https://std.stheadline.com/realtime/article/1813919/%E5%8D%B3%E6%99%82-%E5%9C%8B%E9%9A%9B-%E7%BE%8E%E5%9C%8B%E7%A0%94%E7%A9%B6%E6%8C%87%E8%BC%9D%E7%91%9E%E7%96%AB%E8%8B%97%E5%B0%8D5%E8%87%B311%E6%AD%B2%E4%BF%9D%E8%AD%B7%E7%8E%871%E5%80%8B%E5%8D%8A%E6%9C%88%E5%BE%8C%E9%99%8D%E8%87%B312-%E6%88%96%E8%88%87%E5%8A%91%E9%87%8F%E6%9C%89%E9%97%9C
Onlok 發表於 22-3-1 17:46
有無新聞link?
https://std.stheadline.com/realtime/article/1813919/%E5%8D%B3%E6%99%82-%E5%9C%8B%E9%9A%9B-%E7%BE%8E%E5%9C%8B%E7%A0%94%E7%A9%B6%E6%8C%87%E8%BC%9D%E7%91%9E%E7%96%AB%E8%8B%97%E5%B0%8D5%E8%87%B311%E6%AD%B2%E4%BF%9D%E8%AD%B7%E7%8E%871%E5%80%8B%E5%8D%8A%E6%9C%88%E5%BE%8C%E9%99%8D%E8%87%B312-%E6%88%96%E8%88%87%E5%8A%91%E9%87%8F%E6%9C%89%E9%97%9C
kt1 發表於 22-3-1 17:48
https://std.stheadline.com/realtime/article/1813919/%E5%8D%B3%E6%99%82-%E5%9C%8B%E9%9A%9B-%E7%BE%8 ...
本帖最後由 Jasmine-4711 於 22-3-1 18:15 編輯
睇左, 多謝樓主分享
家長係有知情權
“獅子山下”精神,
香港人要互相幫助, 齊心抗疫.
"跌到"12%,不是"跌了"12%
仍可防重症嗎?
而且輕症兒童冇床位入院,
醫院數字可能不包括入院（家中隔離的）,
輕症都可以喉龍痛到死下死下,
上BK求救問大家食咩藥好,
輕症仲可能有後遺,
家長唔想自己子女受苦,
要三思
ps.我一家大細都打科與
Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant[size=1.05][size=1.05]Vajeera Dorabawila, Dina Hoefer, Ursula E Bauer, Mary Bassett, Emily Lutterloh, Eli Rosenberg
[size=0.82][size=1.05][size=1.05]doi: https://doi.org/10.1101/2022.02.25.22271454
Importance: There is limited evidence on the effectiveness of the BNT162b2 vaccine for children, particularly those 5-11 years and after the Omicron variant's emergence. Objective: To estimate BNT162b2 vaccine effectiveness against COVID cases and hospitalizations among children 5-11 years and 12-17 years during December, 2021 and January, 2022. Design: Analyses of cohorts constructed from linked statewide immunization, laboratory testing, and hospitalization databases. Setting/Participants: New York State children 5-17 years. Main outcomes/measures: New laboratory-confirmed COVID-19 cases and hospitalizations. Comparisons were made using the incidence rate ratio (IRR), comparing outcomes by vaccination status, and estimated vaccine effectiveness (VE: 1-[1/IRR]). Results: From December 13, 2021 to January 30, 2022, among 852,384 fully-vaccinated children 12-17 years and 365,502 children 5-11 years, VE against cases declined from 66% (95% CI: 64%, 67%) to 51% (95% CI: 48%, 54%) for those 12-17 years and from 68% (95% CI: 63%, 72%) to 12% (95% CI: 6%, 16%) for those 5-11 years. During the January 24-30 week, VE for children 11 years was 11% (95%CI -3%, 23%) and for those age 12 was 67% (95% CI: 62%, 71%). VE against hospitalization declined changed from 85% (95% CI: 63%, 95%) to 73% (95% CI: 53%, 87%) for children 12-17 years, and from 100% (95% CI: -189%, 100%) to 48% (95% CI: -12%, 75%) for those 5-11 years. Among children newly fully-vaccinated December 13, 2021 to January 2, 2022, VE against cases within two weeks of full vaccination for children 12-17 years was 76% (95% CI: 71%, 81%) and by 28-34 days it was 56% (95% CI: 43%, 63%). For children 5-11, VE against cases declined from 65% (95% CI: 62%, 68%) to 12% (95% CI: 8%, 16%) by 28-34 days. Conclusions and Relevance: In the Omicron era, the effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11 years. However, vaccination of children 5-11 years was protective against severe disease and is recommended. These results highlight the potential need to study alternative vaccine dosing for children and the continued importance layered protections, including mask wearing, to prevent infection and transmission.
https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1
返回列表
